Back to Parexel Insights

Navigating tension of clinical equipoise in precision oncology trials

By Amy McKee, M.D., Chief Medical Officer & Global Head, Oncology Center of Excellence
Matthew Gordon, Vice President, Real-World Evidence Strategy
Stacy Hurt, M.H.A., M.B.A., Chief Patient Officer
Gwyn Bebb, M.D., BM, BCh, Ph.D., Senior Vice President, Global Therapeutic Area Head – Oncology
Amy Pace, ScD, Vice President, Biostatistics

45 min

Precision oncology has transformed cancer treatment, offering personalized therapies based on genetic and molecular profiles. However, as the field advances, so do the complexities.

In this roundtable discussion, Parexel experts cover diverse perspectives and explore the delicate balance in determining equipoise between standard-of-care treatments and scientific advancements in precision oncology.  This esteemed panel delves into the challenges and opportunities in navigating tensions while ensuring patient safety and scientific rigor.

Topics covered include:

  • Clinical Equipoise in Precision Oncology Trials
  • Hybrid Trial Designs
  • Regulatory Insights
  • Patient-Centric Approaches

COntributing Experts

Gwyn Bebb, M.D., BM, BCh, Ph.D.

Senior Vice President, Global Therapeutic Area Head – Oncology

Read bio

Amy McKee, M.D.

Chief Medical Officer & Global Head, Oncology Center of Excellence

Read bio

Matthew Gordon

Vice President, Real-World Evidence Strategy

Read bio

Amy Pace, ScD

Vice President, Biostatistics

Read bio

Stacy Hurt, M.H.A., M.B.A.

Chief Patient Officer

Read bio

Learn what's possible now

Stay current with novel thinking and actionable insights from our experts.

Start a conversation

Learn more about how Parexel is advancing precision oncology

The vision of precision oncology—to treat each patient with the exact right medicine—is within reach yet still remote. We will move closer to the long-term vision by solving practical short-term problems and prioritizing innovation. At Parexel, we navigate multi-omics profiling, biomarkers, dose optimization, clinical trial site selection, companion diagnostics, regulatory strategy, and commercialization one challenge at a time while staying focused on improving the patient journey, our North Star. 

Our oncology-focused patient advocates, scientists, statisticians, and former regulators are proud to partner with sponsors to advance precision oncology.

Learn More